SCHEMBL25742001

SCHEMBL25742001

Cn1cc(C(=O)C(N)CO)c2ccc(F)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.47
TDO2 P48775 1/20 0.47
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
DRD2 P14416 1/20 0.38
SLC6A4 P31645 1/20 0.38
CNR2 P34972 2/20 0.38
CDK2 P24941 1/20 0.38
CNR1 P21554 1/20 0.37
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 2/20 0.36
MITF O75030 1/20 0.36
MAPT P10636 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HTT P42858 1/20 0.36
ICMT O60725 2/20 0.36
PCSK9 Q8NBP7 1/20 0.35
HTR3A P46098 1/20 0.35
HAT1 O14929 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25742028 0.90 KDM4E (0.46) IDO1TDO2KMT2AMEN1DRD2
SCHEMBL25742002 0.85 CNR1 (0.43) KMT2AMEN1CNR2CNR1LMNA
SCHEMBL25742017 0.84 KMT2A (0.39) KMT2AMEN1CNR2CDK2CNR1
SCHEMBL25742011 0.82 IDO1 (0.46) IDO1TDO2KMT2AMEN1DRD2
SCHEMBL25742014 0.80 IDO1 (0.44) IDO1TDO2KMT2AMEN1DRD2
SCHEMBL30568918 0.79 IDO1 (0.54) IDO1TDO2KMT2AMEN1DRD2
SCHEMBL25742051 0.77 IDO1 (0.45) IDO1TDO2KMT2AMEN1DRD2
SCHEMBL2439483 0.77 IDO1 (0.49) IDO1TDO2KMT2AMEN1DRD2
SCHEMBL30568943 0.77 IDO1 (0.49) IDO1TDO2KMT2AMEN1DRD2
SCHEMBL25742076 0.77 IDO1 (0.43) IDO1TDO2KMT2AMEN1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257347-A1 ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-08-17 US disclosed
US-20230257347-A1 ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-08-17 US disclosed
WO-2023107715-A1 SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT TACTOGEN INC (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257347-A1 ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT HTR6, TPH2, TPH1 IDO1 347/4885TDO2 180/4885KMT2A 1439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.